The Fallacy of the CE Mark (Revised Content)

Due to a Notice of Concern issued under s14(2) of the Defamation Act 2005 (NSW) by Oncosil Limited (ASX : OSL), this content has been re-posted without any reference to OSL. Thanks to readers who gave me feedback that the content was useful and should be re-posted in a redacted form. Everyone loves the CE (Conformité…

Erratum? BNC210

Firstly, in the interest of being positive, congratulations to Bionomics (ASX : BNO) on all the recent positive coverage on the Merck relationship. No matter how you feel about the company, its prospects, or the way it goes about doing things, it’s pretty impressive to have a major-league pharma partner like that. Of course, it is somewhat…

“Pleading Schultz” : Possunt quia posse videntur

I’d like to be serious for a moment and pay kind tribute to my esteemed colleague, Mr. David Langsam, Senior Editor of the Biotech Daily. To begin with, I would like to acknowledge David, with thanks and grace, for his jolly decent shout out in an earlier edition of his daily circular. It was wholly unexpected…

ACL : Erratum (Mr. Ken Poutakidis)

By way of follow-up to my previous post on Alchemia (ASX : ACL), I have been informed that my implied statement that Mr Ken Poutakidis, who recently joined the struggling board of ACL, was previously a director of Phosphagenics (ASX : POH) is in fact incorrect. I made a determination on the basis of reasonable information that was…

Almost Antisensible : Correction

Normally I pride myself on being reasonably thorough when I comment on a company. In this instance (my prior post), I was sloppy and I apologise, I did not look closely at the other ASX disclosures around the deal and missed the Appendix 3B filing. I will not make excuses but I figure if paid-up…